3 completed. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow Other Solid Tumors: new trials by email Literature Review of Other Solid Tumors trials Research Report on Other Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment Selinexor 100 mg, Docetaxel, Pembrolizumab - Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Completed | Karyopharm Therapeutics Inc | 80 | 2020-02-09 | 2026-10-09 |
| A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors TALIMOGENE LAHERPAREPVEC (TVEC), Hypofractionated Radiotherapy - Melanoma, Merkel Cell Carcinoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 19 | 2016-06-21 | 2025-01-29 |
| Phase I/II Study of PDR001 in Patients With Advanced Malignancies PDR001 - Melanoma, Non-small Sell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 319 | 2015-04-27 | 2022-08-03 |
Carcinoma, Non-Small-Cell Lung (2) · Melanoma (2) · Carcinoma, Merkel Cell (1) · Colorectal Neoplasms (1) · Thyroid Carcinoma, Anaplastic (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (3) · Neoplasms by Site (3) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Respiratory Tract Diseases (2)
Docetaxel (1) · IFL protocol (1) · Radiation Dose Hypofractionation (1) · pembrolizumab (1) · selinexor (1) · spartalizumab (1) · talimogene laherparepvec (1)
Karyopharm Therapeutics Inc (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1)
United States (2) · Canada (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Lebanon (1) · Netherlands (1) · Norway (1) · Poland (1) · Spain (1) · Taiwan (1) · Thailand (1) · Turkey (Türkiye) (1)
2014 (1)